Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Human dose response relation for airborne exposure to Coxiella burnetii

Authors: Russell John Brooke, Mirjam EE Kretzschmar, Nico T Mutters, Peter F Teunis

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

The recent outbreak of Q fever in the Netherlands between 2007 and 2009 is the largest recorded Q fever outbreak. Exposure to Coxiella burnetii may cause Q fever but the size of the population exposed during the outbreak remained uncertain as little is known of the infectivity of this pathogen. The quantification of the infectiousness and the corresponding response is necessary for assessing the risk to the population.

Methods

A human challenge study was published in the 1950s but this study quantified the dose of C. burnetii in relative units. Data from a concurrent guinea pig challenge study were combined with a recent study in which guinea pigs were challenged with a similar aerosol route to quantify human exposure. Concentration estimates for C. burnetii are made jointly with estimates of the dose response parameters in a hierarchical Bayesian framework.

Results

The dose for 50% infection (InfD50%) in human subjects is 1.18 bacteria (95% credible interval (CI) 0.76-40.2). The dose for 50% illness (IllD50) in challenged humans is 5.58 (95%CI 0.89-89.0) bacteria. The probability of a single viable C. burnetii causing infection in humans is 0.44 (95%CI 0.044-0.59) and for illness 0.12 (95%CI 0.0006-0.55).

Conclusions

To our knowledge this is the first human dose–response model for C. burnetii. The estimated dose response relation demonstrates high infectivity in humans. In many published papers the proportion of infected individuals developing illness is reported to be 40%. Our model shows that the proportion of symptomatic infections may vary with the exposure dose. This implies that presence of these bacteria in the environment, even in small numbers, poses a serious health risk to the population.
Appendix
Available only for authorised users
Literature
1.
go back to reference van der Hoek W, Dijkstra F, Schimmer B, Schneeberger PM, Vellema P, Wijkmans C, ter Schegget R, Hackert V, van Duynhoven Y: Q fever in the Netherlands: an update on the epidemiology and control measures. Euro Surveill. 2010, 15 (12): van der Hoek W, Dijkstra F, Schimmer B, Schneeberger PM, Vellema P, Wijkmans C, ter Schegget R, Hackert V, van Duynhoven Y: Q fever in the Netherlands: an update on the epidemiology and control measures. Euro Surveill. 2010, 15 (12):
2.
go back to reference Kampschreur LM, Hagenaars JC, Wielders CC, Elsman P, Lestrade PJ, Koning OH, Oosterheert JJ, Renders NH, Wever PC: Screening for coxiella burnetii seroprevalence in chronic Q fever high-risk groups reveals the magnitude of the Dutch Q fever outbreak. Epidemiol Infect. 2013, 141: 847-851. 10.1017/S0950268812001203.CrossRefPubMed Kampschreur LM, Hagenaars JC, Wielders CC, Elsman P, Lestrade PJ, Koning OH, Oosterheert JJ, Renders NH, Wever PC: Screening for coxiella burnetii seroprevalence in chronic Q fever high-risk groups reveals the magnitude of the Dutch Q fever outbreak. Epidemiol Infect. 2013, 141: 847-851. 10.1017/S0950268812001203.CrossRefPubMed
3.
go back to reference Schimmer B, Ter Schegget R, Wegdam M, Zuchner L, de Bruin A, Schneeberger PM, Veenstra T, Vellema P, van der Hoek W: The use of a geographic information system to identify a dairy goat farm as the most likely source of an urban Q-fever outbreak. BMC Infect Dis. 2010, 10: 69-10.1186/1471-2334-10-69.CrossRefPubMedPubMedCentral Schimmer B, Ter Schegget R, Wegdam M, Zuchner L, de Bruin A, Schneeberger PM, Veenstra T, Vellema P, van der Hoek W: The use of a geographic information system to identify a dairy goat farm as the most likely source of an urban Q-fever outbreak. BMC Infect Dis. 2010, 10: 69-10.1186/1471-2334-10-69.CrossRefPubMedPubMedCentral
4.
go back to reference Dijkstra F, van der Hoek W, Wijers N, Schimmer B, Rietveld A, Wijkmans CJ, Vellema P, Schneeberger PM: The 2007–2010 Q fever epidemic in the Netherlands: characteristics of notified acute Q fever patients and the association with dairy goat farming. FEMS Immunol Med Microbiol. 2012, 64 (1): 3-12. 10.1111/j.1574-695X.2011.00876.x.CrossRefPubMed Dijkstra F, van der Hoek W, Wijers N, Schimmer B, Rietveld A, Wijkmans CJ, Vellema P, Schneeberger PM: The 2007–2010 Q fever epidemic in the Netherlands: characteristics of notified acute Q fever patients and the association with dairy goat farming. FEMS Immunol Med Microbiol. 2012, 64 (1): 3-12. 10.1111/j.1574-695X.2011.00876.x.CrossRefPubMed
7.
go back to reference Russell-Lodrigue KE, Zhang GQ, McMurray DN, Samuel JE: Clinical and pathologic changes in a guinea pig aerosol challenge model of acute Q fever. Infect Immun. 2006, 74 (11): 6085-6091. 10.1128/IAI.00763-06.CrossRefPubMedPubMedCentral Russell-Lodrigue KE, Zhang GQ, McMurray DN, Samuel JE: Clinical and pathologic changes in a guinea pig aerosol challenge model of acute Q fever. Infect Immun. 2006, 74 (11): 6085-6091. 10.1128/IAI.00763-06.CrossRefPubMedPubMedCentral
8.
go back to reference Schwebach JR, Chen B, Glatman-Freedman A, Casadevall A, McKinney JD, Harb JL, McGuire PJ, Barkley WE, Bloom BR, Jacobs WR: Infection of mice with aerosolized mycobacterium tuberculosis: use of a nose-only apparatus for delivery of low doses of inocula and design of an ultrasafe facility. Appl Environ Microbiol. 2002, 68 (9): 4646-4649. 10.1128/AEM.68.9.4646-4649.2002.CrossRefPubMedPubMedCentral Schwebach JR, Chen B, Glatman-Freedman A, Casadevall A, McKinney JD, Harb JL, McGuire PJ, Barkley WE, Bloom BR, Jacobs WR: Infection of mice with aerosolized mycobacterium tuberculosis: use of a nose-only apparatus for delivery of low doses of inocula and design of an ultrasafe facility. Appl Environ Microbiol. 2002, 68 (9): 4646-4649. 10.1128/AEM.68.9.4646-4649.2002.CrossRefPubMedPubMedCentral
9.
go back to reference Mosby’s medical dictionary. 2008, St Louis, MO: Mosby/Elsevier, 8 Mosby’s medical dictionary. 2008, St Louis, MO: Mosby/Elsevier, 8
10.
go back to reference Guyton AC: Measurement of the respiratory volumes of laboratory animals. Am J Physiol. 1947, 150 (1): 70-77.PubMed Guyton AC: Measurement of the respiratory volumes of laboratory animals. Am J Physiol. 1947, 150 (1): 70-77.PubMed
11.
go back to reference Teunis PF, Havelaar AH: The beta Poisson dose–response model is not a single-hit model. Risk Anal. 2000, 20 (4): 513-520. 10.1111/0272-4332.204048.CrossRefPubMed Teunis PF, Havelaar AH: The beta Poisson dose–response model is not a single-hit model. Risk Anal. 2000, 20 (4): 513-520. 10.1111/0272-4332.204048.CrossRefPubMed
12.
go back to reference Abramowitz M, Stegun IA: Handbook of mathematical functions with formulas, graphs, and mathematical tables. 1965, Dover Publications: New York: Dover Abramowitz M, Stegun IA: Handbook of mathematical functions with formulas, graphs, and mathematical tables. 1965, Dover Publications: New York: Dover
13.
go back to reference Teunis PF, Nagelkerke NJ, Haas CN: Dose response models for infectious gastroenteritis. Risk Anal. 1999, 19 (6): 1251-1260.PubMed Teunis PF, Nagelkerke NJ, Haas CN: Dose response models for infectious gastroenteritis. Risk Anal. 1999, 19 (6): 1251-1260.PubMed
14.
go back to reference Teunis PF, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, Le Pendu J, Calderon RL: Norwalk virus: how infectious is it?. J Med Virol. 2008, 80 (8): 1468-1476. 10.1002/jmv.21237.CrossRefPubMed Teunis PF, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, Le Pendu J, Calderon RL: Norwalk virus: how infectious is it?. J Med Virol. 2008, 80 (8): 1468-1476. 10.1002/jmv.21237.CrossRefPubMed
15.
go back to reference Plummer M, Best N, Cowles K, Vines K: CODA: convergence diagnosis and output analysis for MCMC. R News. 2006, 6 (1): 7-11. Plummer M, Best N, Cowles K, Vines K: CODA: convergence diagnosis and output analysis for MCMC. R News. 2006, 6 (1): 7-11.
17.
go back to reference van der Hoek W, Hogema BM, Dijkstra F, Rietveld A, Wijkmans CJ, Schneeberger PM, Zaaijer HL: Relation between Q fever notifications and coxiella burnetii infections during the 2009 outbreak in the Netherlands. Euro Surveill. 2012, 17 (3): 20058-PubMed van der Hoek W, Hogema BM, Dijkstra F, Rietveld A, Wijkmans CJ, Schneeberger PM, Zaaijer HL: Relation between Q fever notifications and coxiella burnetii infections during the 2009 outbreak in the Netherlands. Euro Surveill. 2012, 17 (3): 20058-PubMed
18.
go back to reference Karagiannis I, Schimmer B, Van Lier A, Timen A, Schneeberger P, Van Rotterdam B, De Bruin A, Wijkmans C, Rietveld A, Van Duynhoven Y: Investigation of a Q fever outbreak in a rural area of the Netherlands. Epidemiol Infect. 2009, 137 (9): 1283-1294. 10.1017/S0950268808001908.CrossRefPubMed Karagiannis I, Schimmer B, Van Lier A, Timen A, Schneeberger P, Van Rotterdam B, De Bruin A, Wijkmans C, Rietveld A, Van Duynhoven Y: Investigation of a Q fever outbreak in a rural area of the Netherlands. Epidemiol Infect. 2009, 137 (9): 1283-1294. 10.1017/S0950268808001908.CrossRefPubMed
19.
go back to reference Schimmer B, Morroy G, Dijkstra F, Schneeberger PM, Weers-Pothoff G, Timen A, Wijkmans C, van der Hoek W: Large ongoing Q fever outbreak in the south of the Netherlands, 2008. Euro Surveill. 2008, 13 (31): Schimmer B, Morroy G, Dijkstra F, Schneeberger PM, Weers-Pothoff G, Timen A, Wijkmans C, van der Hoek W: Large ongoing Q fever outbreak in the south of the Netherlands, 2008. Euro Surveill. 2008, 13 (31):
20.
go back to reference Tamrakar SB, Haluska A, Haas CN, Bartrand TA: Dose–response model of coxiella burnetii (Q fever). Risk Anal. 2011, 31 (1): 120-128. 10.1111/j.1539-6924.2010.01466.x.CrossRefPubMed Tamrakar SB, Haluska A, Haas CN, Bartrand TA: Dose–response model of coxiella burnetii (Q fever). Risk Anal. 2011, 31 (1): 120-128. 10.1111/j.1539-6924.2010.01466.x.CrossRefPubMed
21.
go back to reference Andoh M, Russell-Lodrigue KE, Zhang G, Samuel JE: Comparative virulence of phase I and II coxiella burnetii in immunodeficient mice. Ann N Y Acad Sci. 2005, 1063: 167-170. 10.1196/annals.1355.026.CrossRefPubMed Andoh M, Russell-Lodrigue KE, Zhang G, Samuel JE: Comparative virulence of phase I and II coxiella burnetii in immunodeficient mice. Ann N Y Acad Sci. 2005, 1063: 167-170. 10.1196/annals.1355.026.CrossRefPubMed
22.
go back to reference Teunis PF, Ogden ID, Strachan NJ: Hierarchical dose response of E. coli O157:H7 from human outbreaks incorporating heterogeneity in exposure. Epidemiol Infect. 2008, 136 (6): 761-770.CrossRefPubMed Teunis PF, Ogden ID, Strachan NJ: Hierarchical dose response of E. coli O157:H7 from human outbreaks incorporating heterogeneity in exposure. Epidemiol Infect. 2008, 136 (6): 761-770.CrossRefPubMed
23.
go back to reference DuMouchel WH, Harris JE: Bayes methods for combining the results of cancer studies in humans and other species. J Am Stat Assoc. 1983, 78 (382): 293-308. 10.1080/01621459.1983.10477968.CrossRef DuMouchel WH, Harris JE: Bayes methods for combining the results of cancer studies in humans and other species. J Am Stat Assoc. 1983, 78 (382): 293-308. 10.1080/01621459.1983.10477968.CrossRef
24.
go back to reference Amano K, Williams JC, Missler SR, Reinhold VN: Structure and biological relationships of coxiella burnetii lipopolysaccharides. J Biol Chem. 1987, 262 (10): 4740-4747.PubMed Amano K, Williams JC, Missler SR, Reinhold VN: Structure and biological relationships of coxiella burnetii lipopolysaccharides. J Biol Chem. 1987, 262 (10): 4740-4747.PubMed
25.
go back to reference Scott GH, Williams JC, Stephenson EH: Animal models in Q fever: pathological responses of inbred mice to phase I coxiella burnetii. J Gen Microbiol. 1987, 133 (3): 691-700.PubMed Scott GH, Williams JC, Stephenson EH: Animal models in Q fever: pathological responses of inbred mice to phase I coxiella burnetii. J Gen Microbiol. 1987, 133 (3): 691-700.PubMed
26.
go back to reference Herremans T, Hogema BM, Nabuurs M, Peeters M, Wegdam-Blans M, Schneeberger P, Nijhuis C, Notermans DW, Galama J, Horrevorts A, et al: Comparison of the performance of IFA, CFA, and ELISA assays for the serodiagnosis of acute Q fever by quality assessment. Diagn Microbiol Infect Dis. 2013, 75 (1): 16-21. 10.1016/j.diagmicrobio.2012.09.001.CrossRefPubMed Herremans T, Hogema BM, Nabuurs M, Peeters M, Wegdam-Blans M, Schneeberger P, Nijhuis C, Notermans DW, Galama J, Horrevorts A, et al: Comparison of the performance of IFA, CFA, and ELISA assays for the serodiagnosis of acute Q fever by quality assessment. Diagn Microbiol Infect Dis. 2013, 75 (1): 16-21. 10.1016/j.diagmicrobio.2012.09.001.CrossRefPubMed
27.
go back to reference Anderson AD, Kruszon-Moran D, Loftis AD, McQuillan G, Nicholson WL, Priestley RA, Candee AJ, Patterson NE, Massung RF: Seroprevalence of Q fever in the United States, 2003–2004. Am J Trop Med Hyg. 2009, 81 (4): 691-694. 10.4269/ajtmh.2009.09-0168.CrossRefPubMed Anderson AD, Kruszon-Moran D, Loftis AD, McQuillan G, Nicholson WL, Priestley RA, Candee AJ, Patterson NE, Massung RF: Seroprevalence of Q fever in the United States, 2003–2004. Am J Trop Med Hyg. 2009, 81 (4): 691-694. 10.4269/ajtmh.2009.09-0168.CrossRefPubMed
Metadata
Title
Human dose response relation for airborne exposure to Coxiella burnetii
Authors
Russell John Brooke
Mirjam EE Kretzschmar
Nico T Mutters
Peter F Teunis
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-488

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine